Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP

2021 ◽  
Author(s):  
Parveen Sen ◽  
Aditi Ashok Kumar Agarwal ◽  
Pramod Bhende ◽  
Suganeswari Ganesan
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Outcomes ◽  
Laser Photocoagulation ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Type 1 Rop

Delayed Laser photocoagulation following intravitreal anti–vascular endothelial growth factor injection allows immature retinal vessels to regrow without recurrence of retinopathy of prematurity

2019 ◽  
Author(s):  
Ki Yup Nam ◽  
Ji Eun Lee ◽  
Joo Eun Lee ◽  
Hyun Wong Kim ◽  
Sang Joon Lee
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Laser Photocoagulation ◽  
Retinal Vessel ◽  
Disease Recurrence ◽  
Retinal Vessels ◽  
Vascular Endothelial ◽  
Zone Ii ◽  
Vessel Development ◽  
Endothelial Growth Factor

Abstract Purpose: The effects of delayed laser photocoagulation (LP) for ROP patients who received intravitreal anti–vascular endothelial growth factor injections (IVAs) on peripheral vascularization and disease recurrence in ROP patients. Methods: A total of 26 consecutive infant eyes of 14 patients who received IVA treatments were retrospectively investigated. The patients were divided into two groups depending on the initial treatment as follows: IVA group and prompt LP group. Recurrence of ROP, growth of the retinal vessels, and associated complications were evaluated. Results: There were 16 eyes in the IVA group and 10 eyes in the LP group. In the IVA group, delayed LP was performed in six eyes due to recurrences of ROP. In 16 eyes of the IVA group, the retinal vessels grew upto Zone III in eyes received IVA only. Among the IVA groups, Delayed LP was needed in six eyes due to ROP recurrence following IVA. Delayed LP was performed average 7~8 weeks after IVA, which could give the immature neurovascular tissues time to continue vascular development upto Zone II without further ROP recurrence. However, the prompt LP group did not show vessel development beyond the laser scar. Conclusions: Delayed LP following IVA might provide a chance for retinal vessel development in the immature retina to continue without unexpected ROP recurrences.

scholarly journals Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity

Ophthalmology ◽  
2017 ◽  
Vol 124 (5) ◽  
pp. 619-633 ◽  
Author(s):  
Deborah K. VanderVeen ◽  
Michele Melia ◽  
Michael B. Yang ◽  
Amy K. Hutchinson ◽  
Lorri B. Wilson ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Retinopathy Of Prematurity ◽  
Primary Treatment ◽  
Vascular Endothelial ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document